Loomis, Sayles & Company
AXSM icon

Loomis, Sayles & Company’s Axsome Therapeutics AXSM Stock Holding History

Loomis, Sayles & Company’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$58.6M Sell
239,490
-17,135
-7% -$3.72M 0.07% 101
2026
Q1 		$43.4M Sell
256,625
-58,766
-19% -$10.2M 0.06% 118
2025
Q4 		$57.6M Sell
315,391
-14,734
-4% -$2.06M 0.07% 93
2025
Q3 		$40.1M Buy
330,125
+52,660
+19% +$5.93M 0.05% 136
2025
Q2 		$29M Sell
277,465
-6,705
-2% -$710K 0.04% 179
2025
Q1 		$33.1M Sell
284,170
-5,941
-2% -$677K 0.05% 153
2024
Q4 		$24.5M Sell
290,111
-8,475
-3% -$779K 0.03% 223
2024
Q3 		$26.8M Buy
298,586
+29,497
+11% +$2.57M 0.04% 219
2024
Q2 		$21.7M Sell
269,089
-10,702
-4% -$792K 0.03% 249
2024
Q1 		$22.3M Buy
+279,791
New +$23.5M 0.03% 244

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Loomis, Sayles & Company's AXSM Position: Q2 2026 in Review

Loomis, Sayles & Company reduced its Axsome Therapeutics (AXSM) stake by 6.7% in Q2 2026, selling an estimated $3.72M and leaving 239,490 shares worth $58.6M. The position accounts for 0.07% of the portfolio, ranked #101.

Loomis, Sayles & Company first reported a position in AXSM in Q1 2024 and has held it in 10 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Loomis, Sayles & Company held 239,490 shares of Axsome Therapeutics worth $58.6M as of Q2 2026.
  • Loomis, Sayles & Company sold 17,135 Axsome Therapeutics shares in Q2 2026, an estimated $3.72M.
  • Axsome Therapeutics made up 0.07% of Loomis, Sayles & Company's portfolio in Q2 2026, its #101 holding.
  • Loomis, Sayles & Company first reported a position in Axsome Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Loomis, Sayles & Company's 13F filing for Q2 2026, filed 14 Aug 2026.